Tender detail
Conclusion of a non-exclusive discount agreement for mometasone (solution dosage form only), ATC D07AC13, for 1 January 2027 to 31 December 2028, with one 12-month extension option
Summary
DAK-Gesundheit is seeking non-exclusive pharmaceutical discount agreements for medicines containing the active ingredient mometasone, in solution dosage form only (ATC D07AC13). The agreements are intended to run from 1 January 2027 to 31 December 2028, with an option to extend once for 12 months; they end earlier if an exclusive agreement takes effect.
More tender information after sign-in
The public view shows key tender details. Sign in to open official links, documents and AI tender support.